Regulation of hunger and Satiety: Pharmacotherapy of obesity;Regulation von hunger und sättigung: Pharmakotherapte der adipositas

Pharmazie in Unserer Zeit

Volumn 35, Issue 6, 2006, Pages 500-504

  Schusdziarra, Volker ^a   Erdmann, Johannes ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; AMFEPRAMONE; AMPHETAMINE; CANNABINOID 1 RECEPTOR; CATECHOLAMINE; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; MAZINDOL; MELANIN CONCENTRATING HORMONE; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE GAMMA; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; ANTIOBESITY AGENT;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; GENE CONTROL; HUMAN; HUNGER; MONOTHERAPY; NEUROTRANSMISSION; OBESITY; SATIETY; ANIMAL; DRUG EFFECT; EATING; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; EATING; HUMANS; HUNGER; OBESITY; SATIETY RESPONSE;

EID: 33845313315     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200600195     Document Type: Article

References (17)

1. Schusdziarra, V., Erdmann, J., Schick, R.R.: Rolle des Endocannabinoid-Systems bei der Regulation der Nahrungsaufnahme. In: Schusdziarra, V. (ed.): Das Endocannabinoid-System, Physiologie und Klinische Bedeutung. Uni-Med Verlag, Bremen (2006), in Druck.
2. Schusdziarra, V., Zimmermann, J.P., Schick, R.: Importance of orexigenic counterregulation for multiple targeted feeding inhinbition. Obes. Res. 12 (2004), 627-632.
3. Li, Z., Maglione, M., Tu, W., Mojica, W., Asterburn, D., Shugaman, L.R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P.G., Morton, S.C.: Meta-Analysis: Pharmacologic Treatment of Obesity. Ann. Intern. Med. 142 (2005), 532-546.
4. Wirth, A., Krause, J.: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286 (2001), 1331-1342.
5. Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., Rössner, S.: Effects of the cannabinoid-I receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patient: 1-year experience from the RIO-Europe study. Lancet 365 (2005), 1389-1397.
6. Després, J.P., Golay, A., Sjöström, L.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005), 2121-2134.
7. http://www.aerztezeitung.de/docs/2005/06/21/112a102.asp?cat=
8. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J.: Effect of rimonabant, a cannabinoid-1-receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North-America: a randomized controlled trial. JAMA 295 (2006), 761-75.
9. Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H.P.F., Krempf, M.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352 (1998), 167-172.
10. Torgerson, J.S., Hauptman, J., Boldrin, M.N., Sjöström, L.: Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diab. Care 27 (2004), 155-161.
11. Nauck, M.A.. Meier, J.J.: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Reg. Pept. 128 (2005), 135-148.
12. DeFronzo, R.A., Ratner,, R.E., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D.: Effect of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diab. Care 28 (2005), 1092-1100.
13. Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D.: Effect of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diab. Care 27 (2004), 2628-2635.
14. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S., Baron, A.D.: Effect of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diab. Care 28 (2005), 1083-1091.
15. Heine, R.J., Van Gaal, L.F., Johns, D., Mihm, M.J., Widel, M.H., Brodows, R.G.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Int. Med. 143 (2005), 559-569.
16. Ullrich, A., Erdmann, J., Margraf, J., Schusdziarra, V.: Impact of carbohydrate and fat intake on weight-reducing efficacy of orlistat. Aliment Pharmacol. Ther. 17 (2003), 1007-1013.
17. Anderson, J.W., Konz, E.C., Wood, R.C., Wood, C.L.: Long-term weight-loss maintenance: a meta-analysis of US studies. Am. J. Clin. Nutr. 74 (2001), 579-584.